Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 2, 2006, Pages 301-305

  Kim, Jong Hoon ^a   Kim, Seong Youn ^a   Ahn, Yong Min ^b   Kim, Yong Sik ^b  

^a Gachon University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Antipsychotics; Schizophrenia; Subjective response

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; AUTONOMIC DYSFUNCTION; CONTROLLED STUDY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PATIENT ATTITUDE; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE; CHI-SQUARE DISTRIBUTION; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 33344472676     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.10.006     Document Type: Article

References (34)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 4th edn. 1994 American Psychiatric Press Washington, DC
2. A.G. Awad, L.N. Voruganti, R.J. Heslegrave, and T.P. Hogan Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome Int. Clin. Psychopharmacol. 11 Suppl. 2 1996 55 59
3. T.R. Barnes, and M.A. McPhillips Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics Br. J. Psychiatr., Suppl. 38 1999 34 43
4. G. Chouinard, L. Kopala, A. Labelle, L. Beauclair, S.V. Johnson, and K.I. Singh Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group Can. J. Psychiatry 43 1998 1018 1025
5. J.C. Day, G. Wood, M. Dewey, and R.P. Bentall A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients Br. J. Psychiatry 166 1995 650 653
6. J.C. Day, P. Kinderman, and R. Bentall A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation Acta Psychiatr. Scand. 97 1998 93 97
7. W. Guy Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology (ADM 76-338) 1976 US Department of Health, Education, and Welfare, National Institute for Mental Health Rockville, MD 217 222
8. J.S.E. Hellewell Patients' subjective experiences of antipsychotics: clinical relevance CNS Drugs 16 2002 457 471
9. A. Hofer, G. Kemmler, U. Eder, M. Edlinger, M. Hummer, and W.W. Fleischhacker Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects J. Clin. Psychiatry 65 2004 932 939
10. T.P. Hogan, and A.G. Awad Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures Psychol. Med. 22 1992 347 352
11. T.P. Hogan, A.G. Awad, and R. Eastwood A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity Psychol. Med. 13 1983 177 183
12. H.Y. Jung, J.H. Kim, Y.M. Ahn, S.C. Kim, S.S. Hwang, and Y.S. Kim Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia Hum. Psychopharmacol. 20 2005 41 45
13. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
14. J.H. Kim, H.Y. Jung, U.G. Kang, S.H. Jeong, Y.M. Ahn, and H.J. Byun Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders Mov. Disord. 17 2002 1354 1359
15. J.H. Kim, S.Y. Cho, H.J. Byun, U.G. Kang, Y.M. Ahn, and Y.S. Kim Multidimensional sensory phenomena in antipsychotic-induced akathisia J. Clin. Psychopharmacol. 24 2004 618 623
16. M. Lambert, and D. Naber Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life CNS Drugs 18 Suppl. 2 2004 5 17
17. M. Lambert, P. Conus, P. Eide, R. Mass, A. Karow, and S. Moritz Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence Eur. Psychiatry. 19 2004 415 422
18. M. Lambert, J.M. Haro, D. Novick, E.T. Edgell, L. Kennedy, and M. Ratcliffe Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study Acta Psychiatr. Scand. 111 2005 232 243
19. S. Moritz, M. Krausz, E. Gottwalz, M. Lambert, C. Perro, and S. Ganzer Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics Psychopathology 33 2000 48 51
20. P. Morrison, T. Meehan, D. Gaskill, P. Lunney, and P. Collings Enhancing case managers' skills in the assessment and management of antipsychotic medication side-effects Aust. N. Z. J. Psychiatry 34 2000 814 821
21. D. Naber A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables Int. Clin. Psychopharmacol. 10 Suppl. 3 1995 133 138
22. D. Naber, and A. Karow Good tolerability equals good results: the patient's perspective Eur. Neuropsychopharmacol. 11 Suppl. 4 2001 S391 S396
23. D. Naber, S. Moritz, M. Lambert, F. Rajonk, R. Holzbach, and R. Mass Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs Schizophr. Res. 50 2001 79 88
24. D. Naber, M. Riedel, A. Klimke, E.U. Vorbach, M. Lambert, and K.U. Kuhn Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia Acta. Psychiatr. Scand. 111 2005 106 115
25. D.G.C. Owens A guide to the extrapyramidal side-effects of antipsychotic drugs 1999 Cambridge University Press Cambridge
26. D. Taylor, L. Shapland, G. Laverick, J. Bond, and J. Munro Clozapine - a survey of patient perceptions Psychiatr. Bull. 24 2000 450 452
27. R. Tempier, and N. Pawliuk Influence of novel and conventional antipsychotic medication on subjective quality of life J. Psychiatry Neurosci. 26 2001 131 136
28. T. Van Putten, P.R. May, and S.R. Marder Response to antipsychotic medication: the doctor's and the consumer's view Am. J. Psychiatry 141 1984 16 19
29. L.N. Voruganti, and A.G. Awad Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia Schizophr. Res. 56 2002 37 46
30. L. Voruganti, and A.G. Awad Neuroleptic dysphoria: towards a new synthesis Psychopharmacology 171 2004 121 132
31. L. Voruganti, L. Cortese, L. Oyewumi, Z. Cernovsky, S. Zirul, and A. Awad Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life Schizophr. Res. 43 2000 135 145
32. L. Voruganti, L. Cortese, L. Owyeumi, V. Kotteda, Z. Cernovsky, and S. Zirul Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study Schizophr. Res. 57 2002 201 208
33. J. Waserman, and M. Criollo Subjective experiences of clozapine treatment by patients with chronic schizophrenia Psychiatr. Serv. 51 2000 666 668
34. P. Weiden, B. Rapkin, T. Mott, A. Zygmunt, D. Goldman, and M. Horvitz-Lennon Rating of medication influences (ROMI) scale in schizophrenia Schizophr. Bull. 20 1994 297 310